BioNTech SE - ADR
BNTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$22.13B
Close$
Earnings Call Q4 2025
March 10, 2026 - AI Summary
Strong Financial Performance: BioNTech exceeded its 2025 revenue guidance with total revenues of EUR 2.9 billion, a slight increase from the previous year despite a decrease in COVID-19 vaccine sales. However, R&D expenses were approximately EUR 2.1 billion, slightly lower than the previous year, demonstrating effective cost management.
Healthier Cash Position: The company ended 2025 with EUR 17.2 billion in cash, cash equivalents, and securities, providing a robust financial foundation to support ongoing investments in late-stage oncology programs and potential commercialization efforts.
Transition to New Leadership: Co-founders Ugur Sahin and Ozlem Tureci will transition to a new independent company focused on next-generation mRNA innovations by the end of 2026. This shift raises questions about leadership stability as BioNTech navigates important late-stage trials and product launches, with the next CEO sought to have strong experience in late-stage development and commercial execution.
Exclusive for Stockcircle Pro members
Sign up
$47.83
45.7% downside
Current Fair Value
45.7% downsideOvervalued by 45.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $22.13 Billion |
|---|---|
| Enterprise Value | $13.46 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.51 |
| Beta | 1.25 |
| Outstanding Shares | 253,333,333 |
Return
| Return on Equity | -9.61% |
|---|---|
| Return on Assets | -8.39% |
| Return on Invested Capital | -9.18% |
Valuation & Multiples
| P/E Ratio | -11.56 |
|---|---|
| PEG | -9.98 |
| Price to Sales | 8.81 |
| Price to Book Ratio | 1.26 |
| Enterprise Value to Revenue | 5.09 |
| Enterprise Value to EBIT | -7.97 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-2.40
Average shareholder expectationRevenue Estimate
$180.18 M
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$1.04
Average shareholder expectationRevenue Estimate
$1.32 B
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.5187▼ 74.70% |
|---|---|
| Total Calls | 1,025,660▲ 42.50% |
| Total Puts | 1,557,695▼ 4.48% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 18.61%▼ 0.18% |
|---|---|
| Total Invested | $4.38B▲ 3.83% |
| Investors Holding | 318▲ 16.00% |
ESG Score
No data
About BioNTech SE
7,807 employees
CEO: Ugur Sahin BioNTech SE is a biotechnology firm dedicated to the research, development, and marketing of immunotherapies for oncology and a spectrum of infectious diseases. Its diverse product pipeline features several FixVac candidates, including B...